Paul K Paik
SWOG Cancer Research Network · Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Paul K Paik as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:36 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06031688 · Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)SWOG Cancer Research Network · recruiting · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 · principal investigator
- Ph2NCT04267913 · Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)SWOG Cancer Research Network · withdrawn · Lung Squamous Cell Carcinoma, Recurrent Lung Carcinoma, Stage IV Lung Cancer AJCC v8 · principal investigator
- Ph2NCT02417701 · Sapanisertib in Treating Patients With Stage IV or Recurrent Lung CancerNational Cancer Institute (NCI) · completed · Recurrent Lung Squamous Cell Carcinoma, Stage IV Lung Squamous Cell Carcinoma AJCC v7 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC PatientsR01CA255639 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2021 to 2023 · $581,481 awarded in 2023Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026Named on NCT06031688, NCT04267913
- Cancer Center AdministrationP30CA008748 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ALEX MACDONALD · fiscal years 2013 to 2026Named on NCT02417701
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:36 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.N Engl J Med · 2020725 citationsRCR 29.0
- 117 citationsRCR 8.6
- Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.J Thorac Oncol · 2013110 citationsRCR 2.5
- Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.Clin Cancer Res · 202291 citationsRCR 6.2
- An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.Lung Cancer · 201921 citationsRCR 0.8
- A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion.Cancer Chemother Pharmacol · 201120 citationsRCR 0.5
- Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.Cancer Sci · 202411 citationsRCR 1.4
- Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.Br J Cancer · 20247 citationsRCR 0.9
- Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.Clin Cancer Res · 20257 citationsRCR 1.6